|Printable version||E-mail this to a friend|
ESMA updates MAR guidelines on market soundings
The European Securities and Markets Authority (ESMA) yesterday re-issued the official translations of its final guidelines clarifying the implementation of the Market Abuse Regulation (MAR) for persons receiving market soundings.
Following a linguistic issue in the Polish translation, all 22 language versions are being re-published today which moves its legal application date to 10 January 2017. Today’s publication triggers the period of two months within which national competent authorities subject to these guidelines have to notify ESMA whether or not they intend to comply with the guidelines. However, these updates do not concern the substance of the other guidelines which remains unchanged.
The new market abuse regime strengthens the existing market abuse framework by extending its scope to new markets, platforms and trading behaviors. It contains prohibitions for insider dealing and market manipulation, and provisions to prevent and detect these.
MAR GUIDELINES - PERSONS RECEIVING MARKET SOUNDINGS
2016-1477_MAR_GUIDELINES_-_MARKET_SOUNDINGS.PDF (278.79 KB)
Latest News from
Call for experts in anonymisation of clinical data23/03/2017 16:05:00
The EMA has launched a call for applications to join a technical anonymisation group (TAG) that will help the Agency to further develop best practices for the anonymisation of clinical reports. The goal is to set up a multidisciplinary team with a broad range of expertise.
Health systems: more integration to boost cooperation and reduce gaps in the EU23/03/2017 15:20:00
In its opinion adopted during the plenary session, CoR agrees on the need to improve the integration, cooperation and performance of health systems in the Union. The current health systems in the EU are affected by population ageing, costs of innovative medicine and new technologies, chronic diseases and inequalities in healthcare access.
First anniversary of PRIME – experience so far23/03/2017 15:05:00
The European Medicines Agency (EMA) is organising a meeting with its stakeholders to review the experience gained with its PRIME (PRIority Medicines) scheme one year after it was launched. Registration opens for stakeholder meeting on 19 May 2017.
Smart specialisation strategies: Stronger focus on synergies and interregional cooperation23/03/2017 14:20:00
The regulatory framework around smart specialisation strategies (RIS3) needs to be reformed to increase synergies between the European Structural & Investment Funds and regional innovation & development policies.